mai welcomes aesthetic & wellness center “KLINIQ” on November 7

Bangkok, Market for Alternative Investment (mai) will list

The Klinique Medical Clinic pcl, an aesthetics, plastic surgery, and wellness

center, on November 7, under the ticker symbol “KLINIQ”. The company has a

market capitalization at its initial public offering (IPO) of THB 5.39 billion

(approx. USD 141.77 million).

 

mai President Prapan Charoenprawatt said that KLINIQ would list and start

trading on mai in the Services industry group.

 

KLINIQ provides services on aesthetic dermatology, plastic surgery, and advanced

preventive and holistic health rehabilitation in compliance with medical

principles, consisting of skin disease treatment, cosmetic skin treatment,

weight loss, body contouring, surgery, wellness and regeneration by a team of

medical specialists in aesthetic and cosmetic surgery certified by well-known

institutions in Thailand, the United States and the United Kingdom with

experience in providing medical examination & treatment services in skin

diseases and surgery equipped with advanced technology under the brand “The

Klinique”. As of June 30, 2022, the company has 39 branches in leading

department stores, covering 15 provinces, all over five regions of Thailand. The

39 branches comprise 35 medical clinics, one surgical center at Siam Square in

downtown Bangkok and three nail salons.

 

KLINIQ has a paid-up capital of THB 110 million, consisting of 160 million

existing ordinary shares and 60 million newly issued shares, with a par value of

THB 0.50 each. It offered up to 6 million newly issued shares to the company’s

directors, executives and employees, not over 9 million shares to the company’s

patrons, and at least 45 million shares to institutional investors and

individuals at the underwriters’ discretion, during October 28, 31, and November

1, at THB 24.50 each, for a total of THB 1.47 billion. The IPO price was

equivalent to price-to-earnings ratio (P/E ratio) of 31.78 times. The earnings

per share is equal to THB 0.77, which was calculated from the company’s net

profit of THB 169.60 million in the past four quarters (from July 1, 2021 to

June 30, 2022), divided by fully diluted shares. Daol Securities (Thailand) pcl

is the financial advisor and lead underwriter.

 

KLINIQ’s Chief Executive Officer Apiruj Thongwattana, M.D. said that the company

prioritizes safety and customer satisfaction, and always provides services with

innovative and state-of-the-art medical equipment. It is a must to have the

innovations and medical devices accredited and audited by the United States Food

and Drug Administration (US FDA) and Thailand’s FDA, and tested by the

company’s experienced medical team. The company has recorded continuous growth

based on service enhancement and marketing tools to create awareness of ‘The

Klinique’ brand. The fund raised will be used to expand business, purchase

additional medical equipment, expand surgery center, develop IT systems &

customer database, and as working capital.

 

KLINIQ’s three major shareholders after the IPO are Thongwattana group (52.35

percent), Ekachai Medical Care pcl (7.27 percent), and Rattapol Kittichaitrakul

(7.16 percent). The company’s dividend policy is to pay no less than 40 percent

of net profit from the company’s separate financial statements after corporate

income tax, and legal and other reserves.

 

Source: The Stock Exchange of Thailand

Post Author: web Desk